MX2009006795A - Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma. - Google Patents

Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.

Info

Publication number
MX2009006795A
MX2009006795A MX2009006795A MX2009006795A MX2009006795A MX 2009006795 A MX2009006795 A MX 2009006795A MX 2009006795 A MX2009006795 A MX 2009006795A MX 2009006795 A MX2009006795 A MX 2009006795A MX 2009006795 A MX2009006795 A MX 2009006795A
Authority
MX
Mexico
Prior art keywords
compounds
angiotensin
receptor antagonism
activating activities
ppary
Prior art date
Application number
MX2009006795A
Other languages
English (en)
Inventor
Christopher Franklin Bigge
Agustin Casimiro-Garcia
Lee Chitase
Hud Lawrence Risley
Robert Philip Schaum
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2009006795A publication Critical patent/MX2009006795A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos de fórmula (I) que tienen tanto actividad antagonista de receptor de angiotensina II como actividad agonista de PPARy; (ver fórmula (I)) también se proporcionan composiciones farmacéuticas que comprenden los compuestos y procedimientos de tratamiento de enfermedades con los compuestos incluyendo diabetes tipo 2, resistencia a insulina, hiperinsulinemia, hiperlipidemia, hipertrigliceridemia, síndrome metabólico, fallo cardiaco congestivo, e hipertensión.
MX2009006795A 2006-12-21 2007-12-03 Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma. MX2009006795A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87633406P 2006-12-21 2006-12-21
US97065307P 2007-09-07 2007-09-07
PCT/IB2007/003844 WO2008084303A1 (en) 2006-12-21 2007-12-03 Compounds having both angiotensin ii receptor antagonism and ppary activating activities

Publications (1)

Publication Number Publication Date
MX2009006795A true MX2009006795A (es) 2009-07-03

Family

ID=39284139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006795A MX2009006795A (es) 2006-12-21 2007-12-03 Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.

Country Status (9)

Country Link
US (1) US20100029710A1 (es)
EP (1) EP2125806A1 (es)
JP (1) JP2010513457A (es)
KR (1) KR20090091356A (es)
AU (1) AU2007343139A1 (es)
CA (1) CA2671943A1 (es)
MX (1) MX2009006795A (es)
NO (1) NO20092374L (es)
WO (1) WO2008084303A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664226B2 (en) 2009-04-17 2014-03-04 Kowa Company, Ltd. Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same
WO2010137336A1 (ja) 2009-05-29 2010-12-02 興和株式会社 新規なα－フェノキシベンゼン酢酸誘導体及びこれを含有する医薬
WO2011024468A1 (ja) 2009-08-27 2011-03-03 興和株式会社 新規なスルホンアミド誘導体及びこれを含有する医薬
EP2484675B1 (en) 2009-09-29 2014-11-05 Kowa Company, Ltd. Novel phenylpyridine derivative and medicinal agent comprising same
JP5791150B2 (ja) * 2009-12-15 2015-10-07 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するオキサジアゾール誘導体
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JP2013526610A (ja) 2010-05-24 2013-06-24 ヴァンダービルト ユニバーシティー Ｍｇｌｕｒ５の正のアロステリック調節剤としての置換６−メチルニコチンアミド
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5583841B2 (ja) 2011-03-14 2014-09-03 興和株式会社 新規なフェニルピリジン誘導体及びこれを含有する医薬
US9481659B2 (en) * 2011-05-13 2016-11-01 Celgene International Ii Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
US9135515B2 (en) 2012-10-22 2015-09-15 Qiagen Gaithersburg, Inc. Automated pelletized sample vision inspection apparatus and methods
US9212976B2 (en) 2013-03-15 2015-12-15 Qiagen Gaithersburg, Inc. Vision-guided aspiration apparatus and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure

Also Published As

Publication number Publication date
JP2010513457A (ja) 2010-04-30
KR20090091356A (ko) 2009-08-27
CA2671943A1 (en) 2008-07-17
EP2125806A1 (en) 2009-12-02
AU2007343139A1 (en) 2008-07-17
NO20092374L (no) 2009-09-15
WO2008084303A1 (en) 2008-07-17
US20100029710A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DK1758853T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
WO2009134574A3 (en) Disubstituted phthalazine hedgehog pathway antagonists
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
ECSP12012048A (es) Antagonistas del receptor mineralcorticoide no esteroidal
MX2010001574A (es) Ligandos del receptor cannabinoide.
EA201171125A1 (ru) Антагонист минералокортикоидного рецептора и способы его применения
NZ609596A (en) Cyclohexane derivative compound
PL1805169T3 (pl) Inhibitory receptora histaminowego H3, ich wytwarzanie i zastosowania terapeutyczne
JO2827B1 (en) Mineralocorticoid receptor antagonists and methods of use
UA96967C2 (en) Piperidine gpcr agonists
SE0402640D0 (sv) Pharmaceutical use